ACAD vs TEVA
ACADIA Pharmaceuticals Inc. vs Teva Pharmaceutical Industries Limited — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
| Metric | ACAD | TEVA |
|---|
| AI Score |
69
|
55
|
| Price |
$29.41
|
$36.49
|
| P/E Ratio |
13.07×
|
57.19×
|
| ROE |
31.9%
|
17.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
52.5%
|
| Debt / Equity |
0.06×
|
2.16×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
77.8
|
| Beta |
0.845
|
0.864
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus TEVA.
ACAD leads by 14 points.
ACAD scores 69/100 (Buy) versus TEVA at 55/100 (Watch).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
TEVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 57.5 is expensive by classic value standards — Value
- Price-to-book of 4.9x prices in significant intangible value — Value
- Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value